Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Trial of REGN21353 (a STEAP1xCD3 Bispecific Antibody) Administered Alone or in Combination With Nezastomig (a PSMAxCD28 Bispecific Antibody) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT07850921 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT07850921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07850921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Trial of REGN21353 (a STEAP1xCD3 Bispecific Antibody) Administered Alone or in Combination With Nezastomig (a PSMAxCD28 Bispecific Antibody) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 28, 2027
Completion date
July 28, 2031
Enrollment
192 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc, metastatic castration-resistant prostate cancer